The Pennant Group’s second quarter was marked by strong revenue growth and a positive market response, reflecting management’s focus on operational execution and strategic expansion. CEO Brent Guerisoli credited performance to the company’s emphasis on leadership development, clinical quality, and margin improvement across its service lines. The quarter also benefited from Pennant’s ability to integrate new acquisitions and drive organic growth, especially within its home health and hospice operations. Management highlighted the resilience of its operating model despite challenges in reimbursement and regulatory pressures, with President John Gochnour noting, “Our excellent clinical and cultural performance continues to translate to record financial results.”
Is now the time to buy PNTG? Find out in our full research report (it’s free).
The Pennant Group (PNTG) Q2 CY2025 Highlights:
- Revenue: $219.5 million vs analyst estimates of $210.7 million (30.1% year-on-year growth, 4.2% beat)
- EPS (GAAP): $0.20 vs analyst expectations of $0.24 (17.9% miss)
- Adjusted EBITDA: $16.38 million vs analyst estimates of $16.27 million (7.5% margin, 0.6% beat)
- EPS (GAAP) guidance for the full year is $1.12 at the midpoint, beating analyst estimates by 15.5%
- EBITDA guidance for the full year is $70.9 million at the midpoint, above analyst estimates of $66.83 million
- Operating Margin: 5.3%, in line with the same quarter last year
- Sales Volumes rose 26.1% year on year (35.4% in the same quarter last year)
- Market Capitalization: $926.3 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From The Pennant Group’s Q2 Earnings Call
-
Ben Hendrix (RBC Capital Markets) questioned the strategic rationale behind the UnitedHealth Group and Amedisys acquisition in Tennessee. President John Gochnour explained the decision was influenced by the region’s strong talent pool and prior success with Ensign’s operating model in the state.
-
Ben Hendrix (RBC Capital Markets) asked about the impact of proposed Medicare reimbursement cuts on Pennant’s capitated contracts. Gochnour acknowledged some exposure but highlighted the company’s diversified revenue streams and ability to adapt through operational levers and advocacy.
-
David Samuel MacDonald (Truist) inquired about the sustainability of senior living revenue per occupied bed growth. CEO Brent Guerisoli responded that high single-digit growth is expected to continue, underpinned by ongoing efforts in revenue quality and enhanced resident experience.
-
David Samuel MacDonald (Truist) probed pre-close investments for the UnitedHealth Group and Amedisys deal. Gochnour detailed increased hiring and resource allocation, particularly in leadership and service center functions, to ensure readiness for integration.
-
Stephen Baxter (Wells Fargo) sought details on same-store growth assumptions and margin progression in the updated guidance. CFO Lynette Walbom clarified that the outlook reflects both organic and acquisition-driven growth, with margin expansion expected from operational improvements and new business contributions.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will be watching (1) the pace and effectiveness of integrating the newly acquired UnitedHealth Group and Amedisys portfolio, (2) operational progress in improving margins—particularly in senior living and hospice segments, and (3) any updates on the final 2026 home health rule and Pennant’s adaptations to potential reimbursement changes. The trajectory of organic growth and further M&A activity will also remain key areas of focus.
The Pennant Group currently trades at $26.80, up from $22.27 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.